Harry Fisher – Project Manager – Benchmark’s prices and data empowers clients: from critical mineral contracts to EV battery supply chain investments and government policy.
Copyright 2023 – Finance News Network
Source: Finance News Network
12 Oct 2022 - icetana (ASX:ICE) CEO and Managing Director Matt Macfarlane discusses revenue growth, the company's strategic placement to Macnica, changes to the share registry and the outlook ahead.
Read More07 Jul 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's portfolio of therapies.
Read More12 Apr 2023 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun discusses recent results, strategy, opportunities post lockdown and milestones ahead.
Read More11 Sep 2023 - QANTM Intellectual Property Limited (ASX:QIP) CEO and Managing Director Craig Dower discusses drivers of revenue, competitors and market share, and the company's ambitions to expand into Asia.
Read More27 Jul 2023 - The European Bank for Reconstruction and Development has agreed to invest 6 million euros to support European Metals Holdings' (ASX:EMH) development of the Cinovec lithium project in the Czech Republic.
Read More12 May 2025 - Chairman James Walker discusses funding, contracts, and commercial momentum for 2025.
Read More31 Oct 2023 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress of the company's drug candidates, highlighting promising data from the 2023 ESMO Congress.
Read More20 Aug 2021 - TALi Digital Limited (ASX:TD1) Managing Director Glenn Smith introduces the company’s software for the assessment and treatment of childhood attention difficulties and discusses the company's recent agreement with US company Akili.
Read More06 Nov 2019 - Immutep Limited (ASX:IMM) CEO, Marc Voigt provides an update on the company's clinical trial data for its Phase 1 trial in melanoma, TACTI-mel, where patients are responding positively to the combination therapy of efti and Keytruda.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More
